文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对 gp41 膜近端外部区域 (MPER) 的 HIV 疫苗的开发:挑战与展望。

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

机构信息

State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.

Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences & Shanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China.

出版信息

Protein Cell. 2018 Jul;9(7):596-615. doi: 10.1007/s13238-018-0534-7. Epub 2018 Apr 17.


DOI:10.1007/s13238-018-0534-7
PMID:29667004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6019655/
Abstract

A human immunodeficiency virus type-1 (HIV-1) vaccine which is able to effectively prevent infection would be the most powerful method of extinguishing pandemic of the acquired immunodeficiency syndrome (AIDS). Yet, achieving such vaccine remains great challenges. The membrane-proximal external region (MPER) is a highly conserved region of the envelope glycoprotein (Env) gp41 subunit near the viral envelope surface, and it plays a key role in membrane fusion. It is also the target of some reported broadly neutralizing antibodies (bNAbs). Thus, MPER is deemed to be one of the most attractive vaccine targets. However, no one can induce these bNAbs by immunization with immunogens containing the MPER sequence(s). The few attempts at developing a vaccine have only resulted in the induction of neutralizing antibodies with quite low potency and limited breadth. Thus far, vaccine failure can be attributed to various characteristics of MPER, such as those involving structure and immunology; therefore, we will focus on these and review the recent progress in the field from the following perspectives: (1) MPER structure and its role in membrane fusion, (2) the epitopes and neutralization mechanisms of MPER-specific bNAbs, as well as the limitations in eliciting neutralizing antibodies, and (3) different strategies for MPER vaccine design and current harvests.

摘要

一种能够有效预防感染的人类免疫缺陷病毒 1 型(HIV-1)疫苗将是消灭艾滋病(AIDS)大流行的最有效方法。然而,实现这样的疫苗仍然面临巨大的挑战。膜近端外区(MPER)是包膜糖蛋白(Env)gp41 亚基中靠近病毒包膜表面的高度保守区域,它在膜融合中起关键作用。它也是一些报道的广泛中和抗体(bNAbs)的靶标。因此,MPER 被认为是最有吸引力的疫苗靶标之一。然而,没有人可以通过用含有 MPER 序列的免疫原免疫来诱导这些 bNAbs。少数开发疫苗的尝试仅导致诱导中和抗体的效力和广度相当有限。到目前为止,疫苗失败可归因于 MPER 的各种特征,如结构和免疫学特征;因此,我们将重点关注这些特征,并从以下几个方面回顾该领域的最新进展:(1)MPER 结构及其在膜融合中的作用,(2)MPER 特异性 bNAbs 的表位和中和机制,以及诱导中和抗体的局限性,以及(3)MPER 疫苗设计的不同策略和当前的成果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f15/6019655/721848c5d4ca/13238_2018_534_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f15/6019655/6382b13dc3a0/13238_2018_534_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f15/6019655/64807373195d/13238_2018_534_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f15/6019655/721848c5d4ca/13238_2018_534_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f15/6019655/6382b13dc3a0/13238_2018_534_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f15/6019655/64807373195d/13238_2018_534_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f15/6019655/721848c5d4ca/13238_2018_534_Fig3_HTML.jpg

相似文献

[1]
The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Protein Cell. 2018-4-17

[2]
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

J Virol. 2015-5

[3]
Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.

PLoS One. 2015-6-18

[4]
Neutralizing Antibodies Targeting HIV-1 gp41.

Viruses. 2020-10-23

[5]
Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.

Vaccine. 2006-1-23

[6]
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

J Virol. 2005-1

[7]
Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.

Vaccine. 2017-5-9

[8]
Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.

Virology. 2008-3-30

[9]
Exposure of the HIV-1 broadly neutralizing antibody 10E8 MPER epitope on the membrane surface by gp41 transmembrane domain scaffolds.

Biochim Biophys Acta Biomembr. 2018-2-23

[10]
Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.

Virology. 2017-5

引用本文的文献

[1]
Virus glycoprotein nanodisc platform for vaccine design.

bioRxiv. 2025-6-16

[2]
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics.

MAbs. 2025-12

[3]
Identification of a mimotope of a complex gp41 human immunodeficiency virus epitope related to a non-structural protein of previously implicated in Kawasaki disease.

Microbiol Spectr. 2025-3-31

[4]
Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.

J Virol. 2024-12-17

[5]
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies.

Exp Hematol Oncol. 2024-10-26

[6]
Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation.

Curr Res Microb Sci. 2024-7-22

[7]
Identification of a mimotope of a complex gp41 Human Immunodeficiency VIrus epitope related to a non-structural protein of previously implicated in Kawasaki disease.

bioRxiv. 2024-6-28

[8]
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.

JCI Insight. 2024-4-8

[9]
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein.

N Biotechnol. 2024-5-25

[10]
Molecularly Imprinted Polymer-Based Electrochemical Sensors for the Diagnosis of Infectious Diseases.

Biosensors (Basel). 2023-6-5

本文引用的文献

[1]
HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen.

Emerg Microbes Infect. 2017-11-29

[2]
Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

Front Immunol. 2017-9-19

[3]
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

Sci Immunol. 2017-1-27

[4]
Mechanisms of central tolerance for B cells.

Nat Rev Immunol. 2017-5

[5]
Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.

Proc Natl Acad Sci U S A. 2017-3-20

[6]
Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.

PLoS Pathog. 2017-2-22

[7]
Host controls of HIV broadly neutralizing antibody development.

Immunol Rev. 2017-1

[8]
Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development.

Immunol Rev. 2017-1

[9]
The quest for an antibody-based HIV vaccine.

Immunol Rev. 2017-1

[10]
A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity.

AIDS. 2017-4-24

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索